<DOC>
	<DOCNO>NCT00183794</DOCNO>
	<brief_summary>This study patient advance ovarian cancer reappear treatment conventional therapy . The purpose study determine combination docetaxel gemcitabine effective reduce eliminate tumor ( ) patient ovarian cancer . Docetaxel approve Food Drug Administration ( FDA ) treatment breast lung cancer ; gemcitabine approve FDA treatment pancreatic lung cancer . Neither docetaxel gemcitabine approve treatment ovarian cancer . Both drug show decrease size ovarian cancer tumor .</brief_summary>
	<brief_title>Clinical Trial Docetaxel Combination With Gemcitabine Platinum-Resistant Ovarian Cancer Primary Peritoneal Carcinoma</brief_title>
	<detailed_description>Primary Objective : 1 . To determine response rate , time progression survival ( secondary ) combination docetaxel gemcitabine administer weekly basis patient platinum-resistant ovarian cancer Secondary Objective : 1 . To determine toxicity combination regimen patient platinum-resistant ovarian cancer 2 . To evaluate toxicity safety profile short course ( one dose ) premedication steroid patient receive weekly gemcitabine docetaxel OUTLINE : Patients receive gemcitabine IV 30 minute day 1 8 , docetaxel IV 60 minute day 8 . Treatment repeat every 21 day PD , unacceptable toxicity , patient 's withdrawal .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically proven diagnosis epithelial ovarian ca Must platinumresistant disease . ( Defined progression recent platinumbased chemotx relapse &lt; 6 month recent platinumbased chemotx regimen . ) Measurable evaluable disease . ( Patients whose dz manifest elevated CA125 [ great equal 100 ] eligible . If elevate CA125 manifestation dz , must confirm 2 separate time , least 2 week apart . Patients positive cytology eligible . ) Greater equal 18 year age GOG performance status less equal 2 AGC/ANC great equal 1.5 ; platelet great equal 100,000 ; hemoglobin ( Hgb ) great equal 8.0 . Creatinine le equal 2.0 Total bilirubin less equal upper limit normal ( uln ) SGOT and/or SGPT le equal 2.5 x uln alkaline phosphatase less equal uln , alkaline phosphatase less equal 4 x uln transaminases less equal uln . ( If SGOT/SGPT &gt; 1.5 x uln alkaline phosphatase &gt; 2.5 x uln , patient eligible . ) Fully recover acute toxicity secondary prior treatment ( tx ) Signed informed consent Prior treatment gemcitabine docetaxel Underlying medical , psychiatric , social condition would preclude patient receive treatment Peripheral neuropathy great equal Grade 2 No prior tx cisplatin carboplatin</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Primary Peritoneal</keyword>
</DOC>